Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma

No abstract is available for this paper.

• Publication year

  2001

• Venue

  International Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/PL00012085PMID 11706751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide.

  2000cited by this paper
• Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review).

  2000cited by this paper
• Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia.

  2000cited by this paper
• Concomitant over‐expression of vascular endothelial growth factor and its receptors in pancreatic cancer

  2000cited by this paper
• In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

  1999cited by this paper
• Expression of vascular endothelial growth factor receptors in human prostate cancer.

  1999cited by this paper
• KDR receptor: a key marker defining hematopoietic stem cells.

  1999cited by this paper
• Cancer statistics, 1999

  1999cited by this paper
• Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.

  1999cited by this paper
• Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

  1999cited by this paper
• Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.

  1999cited by this paper
• Vascular endothelial growth factor (VEGF) and its receptors

  1999cited by this paper
• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  1999cited by this paper
• Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src *

  1998cited by this paper
• Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

  1998cited by this paper
• Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

  1998cited by this paper
• HIF‐1α is required for solid tumor formation and embryonic vascularization

  1998cited by this paper
• Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro *

  1998cited by this paper
• Regulation of distinct steps of angiogenesis by different angiogenic molecules.

  1998cited by this paper
• Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells*

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

  1996cited by this paper
• Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.

  1996cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

  1996cited by this paper
• Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.

  1996cited by this paper
• Pancreatic carcinoma in perspective: A continuing challenge

  1996cited by this paper
• Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.

  1996cited by this paper
• Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent (*)

  1996cited by this paper
• Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma.

  1996cited by this paper
• How tumors become angiogenic.

  1996cited by this paper
• Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

  1995cited by this paper
• Regulation of interleukin-8 expression in human melanoma cells by the organ environment.

  1995cited by this paper
• Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*)

  1995cited by this paper
• Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.

  1995cited by this paper
• Modulation of the organ microenvironment for treatment of cancer metastasis.

  1995influential reference
• Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

  1995cited by this paper
• Critical factors in the biology of human cancer metastasis.

  1995influential reference
• Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.

  1995cited by this paper
• Angiogenesis: models and modulators.

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.

  1995cited by this paper
• Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

  1994cited by this paper
• Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice.

  1994influential reference
• The implications of angiogenesis for the biology and therapy of cancer metastasis.

  1994cited by this paper
• Cytokine networks in solid human tumors: regulation of angiogenesis

  1994cited by this paper
• Angiogenesis inhibition: a review.

  1994cited by this paper
• Trends in pancreatic cancer mortality in Europe, 1955–1989

  1994cited by this paper
• Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells.

  1994cited by this paper
• Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

  1994cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival.

  1993cited by this paper
• In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse

  1992cited by this paper
• Metastatic model for human prostate cancer using orthotopic implantation in nude mice.

  1992cited by this paper
• Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

  1992cited by this paper
• Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

  1991cited by this paper
• Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

  1991cited by this paper
• Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

  1990cited by this paper
• Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

  1989cited by this paper
• The distribution of secondary growths in cancer of the breast. 1889.

  1989cited by this paper
• Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.

  1989cited by this paper
• Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.

  1989cited by this paper
• In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice.

  1988cited by this paper
• A new in vivo model to study invasion and metastasis of human bladder carcinoma.

  1987cited by this paper
• Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice.

  1987cited by this paper
• Angiogenic factors.

  1987cited by this paper
• Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases.

  1986cited by this paper
• Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice.

  1986cited by this paper
• Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice.

  1986cited by this paper
• Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell.

  1986cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma

  1980cited by this paper
• Metastasis results from preexisting variant cells within a malignant tumor.

  1977cited by this paper
• Selection of successive tumour lines for metastasis.

  1973cited by this paper
• [Cancer of the pancreas].

  1965cited by this paper

• From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy

  2025cites this paper
• Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.

  2023cites this paper
• Prognostic correlation of breast neoplasm with MAGS (Microscopic Angiogenesis Grading System) score

  2014cites this paper
• Análise da densidade da microvasculatura e da expressão do gene p53 no adenocarcinoma pancreático

  2009cites this paper
• Small molecule tyrosine kinase inhibitors in pancreatic cancer

  2008cites this paper
• Antiangiogenic drugs: current knowledge and new approaches to cancer therapy.

  2008cites this paper
• Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?

  2006cites this paper
• Induction of autoantibodies to cathepsin L as a step towards an anti-cancer vaccine.

  2005cites this paper
• Microwave Detection of Metastasized Breast Cancer Cells in the Lymph Node; Potential Application for Sentinel Lymphadenectomy

  2004cites this paper
• A new liver metastatic and peritoneal dissemination model established from the same human pancreatic cancer cell line: Analysis using cDNA macroarray

  2004cites this paper
• Neoadjuvant therapy for resectable pancreatic cancer.

  2004cites this paper
• A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile

  2004cites this paper
• Pathways for aberrant angiogenesis in pancreatic cancer

  2003cites this paper
• Therapeutic strategies using inhibitors of angiogenesis.

  2003cites this paper
• Expression of Vascular Endothelial Growth Factor and p53 in Pancreatic Carcinomas

  2002cites this paper